US Stock MarketDetailed Quotes
BTAI BioXcel Therapeutics
- 0.667
- -0.047-6.61%
Close Oct 31 16:00 ET
- 0.650
- -0.017-2.52%
Post 20:02 ET
27.17MMarket Cap-192P/E (TTM)
0.724High0.640Low413.63KVolume0.714Open0.714Pre Close274.43KTurnover1.40%Turnover RatioLossP/E (Static)40.74MShares5.62052wk High-0.37P/B19.78MFloat Cap0.50552wk Low--Dividend TTM29.66MShs Float71.500Historical High--Div YieldTTM11.70%Amplitude0.505Historical Low0.663Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
BioXcel Therapeutics Stock Forum
BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...
NEWS
BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
BioXcel Therapeutics (Nasdaq: BTAI) has announced that Dr. Rob Risinger will present both oral and poster presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting from May 28 to 31 in Miami Beach, FL. The presentations will focus on the comparison of sublingual Dexmedetomidine wit...
No comment yet